Business Wire

Adva Network Security launches Security Director to automate cryptographic operations and network security

30.9.2025 10:00:00 EEST | Business Wire | Press release

Share

Adva Network Security today launched Security Director, a new software solution that automates security-critical processes and simplifies regulatory compliance. By replacing manual tasks with automation, Security Director minimizes human error and improves control over cryptographic and password-based systems. It also provides real-time compliance scores based on German, EU and international security standards, so IT teams can see where they stand at a glance. The platform also integrates with existing security operations centers (SOCs), enabling faster incident response and streamlined operations across distributed environments. Available as a standalone product, Security Director represents a significant advancement in scalable, software-driven infrastructure security.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250929431154/en/

Adva Network Security’s new Security Director will help organizations automate security-critical processes and simplify regulatory compliance.

“Security Director is designed to radically simplify complex and labor-intensive security tasks,” said Michael Roth, GM of Adva Network Security. “Automating processes such as credential rotation, secure configuration and compliance checks takes pressure off overstretched IT teams, removing virtually all manual intervention and ensuring greater accuracy in daily operations. For organizations managing distributed, resource-constrained environments, this means stronger protection against threats, fewer errors and the confidence that critical services will remain secure and available.”

Security Director automates secure key exchange between encryption endpoints using password-based authentication or fingerprint-style pairing, protecting against man-in-the-middle attacks. It also streamlines secure staging, setup of embedded PKI systems for managing encryption keys and certificates, and password orchestration for privileged accounts and crypto credentials. A built-in compliance engine checks over 20 key configuration settings, from password strength to protocol use, and generates a percentage score aligned with policy. These tools give operators vital insight into cryptographic posture while reducing risk exposure. Security Director is designed for deployment in private cloud environments, offering a flexible and scalable architecture for secure service delivery. Devices currently supported include the Adtran FSP 150-XG118Pro (CSH), with future expansion to the Adtran FSP 3000 platform.

“Our customers are facing rising network complexity and stringent audit and accountability demands. There’s also a growing shortage of skilled workers, making security management increasingly challenging,” commented Josef Sißmeir, GM of Adva Network Security. “Security Director significantly reduces the burden on IT teams, strengthens compliance with regulations like NIS2 and supports secure network operation through comprehensive automation. With a choice of subscription options, IT teams can select the capabilities they need to minimize their attack surface and ensure the critical infrastructure they operate remains resilient and protected.”

About Adva Network Security

Adva Network Security is a leading German IT-security company. We provide robust optical and Ethernet networking solutions and a comprehensive service offering. Our ConnectGuard technology delivers quantum-safe encryption that protects large-scale networks and essential applications. Critical infrastructure, government, defense and enterprise customers rely on our technical expertise in communication networks and information security. This unique combination of skills ensures the resilience and security of their essential IT and OT infrastructure. Customers can count on our services team from initial design to secure operation, ensuring business continuity amid growing cyber threats. Our design, manufacturing processes and security solutions are certified by leading government security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250929431154/en/

Contacts

For media
Antje Hartmann
t +49 30 2636969166
info@advasecurity.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye